
zzso spread of cancer to distant zzso responsible for most cancer zzso Current zzso therapy is based on zzso indicators that zzso patients into defined risk zzso However, some patients believed to have a good prognosis nonetheless develop zzso in some cases many years after apparently successful treatment of their primary zzso This period of clinical dormancy leads to many questions about how best to manage patients, including how to better assign risk of late zzso how long to monitor patients, and whether some patients will benefit from extended therapy to prevent late zzso The development of targeted therapies with fewer side effects is leading to clinical trials aimed at determining the effectiveness of such long-term zzso However, much remains to be learned about tumor zzso Experimental studies are shedding light on biological and molecular mechanisms potentially responsible for tumor zzso Emerging research into tumor initiating cells, zzso and zzso zzso zzso may lead to new approaches for targeted zzso therapy to prolong tumor zzso An improved understanding of tumor dormancy is needed for better management of patients at risk for zzso zzso 

